Try our beta test site
904 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
21 Recruiting Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR TKI Therapy
Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4;   Non-Small Cell Lung Cancer;   EGFR Gene Mutation
22 Recruiting NY-ESO-1 TCR (TAEST16001)for Patients With Advanced NSCLC
Condition: Lung Cancer, Nonsmall Cell, Recurrent
Interventions: Drug: Cyclophosphamide;   Biological: Anti-NY-ESO-1 TCR transduced T cells
23 Recruiting A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Atezolizumab;   Drug: Daratumumab
24 Not yet recruiting Evaluation of a Food Intake Modification for Lung Cancer Patients
Conditions: Carcinoma, Non-Small-Cell Lung;   Antineoplastic Agents
Interventions: Other: Food Intake Modification;   Other: Habitual Food Intake
25 Recruiting A Study of Durvalumab Versus Standard of Care in Advanced Non Small-Cell Lung Cancer
Condition: Non Small Cell Lung Carcinoma (NSCLC)
Interventions: Biological: Durvalumab (MEDI4736);   Drug: Paclitaxel + carboplatin;   Drug: Gemcitabine + cisplatin;   Drug: Gemcitabine + carboplatin;   Drug: Pemetrexed + cisplatin;   Drug: Pemetrexed + carboplatin
26 Not yet recruiting EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
Conditions: Nonsmall Cell Lung Cancer;   EGFR Gene Mutation
Interventions: Drug: EGFR-TK Inhibitor;   Drug: EGFR-TKI;   Drug: EGFR-TKI and Chemotherapy
27 Recruiting Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: 14C-labeled AC0010 oral
28 Not yet recruiting Combination Study of Guadecitabine and Pembrolizumab.
Conditions: Castration-Resistant Prostatic Cancer;   Non Small Cell Lung Cancer
Interventions: Drug: Guadecitabine;   Drug: Pembrolizumab
29 Recruiting Single-port, Two-port Versus Three-port VATS on Non-small Cell Lung Cancer
Condition: Lung Neoplasm
Interventions: Procedure: Three-port pulmonary resection surgery;   Procedure: Single-port or two-port surgery
30 Not yet recruiting EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC
Condition: Nonsmall Cell Lung Cancer
31 Recruiting A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Condition: NSCLC
Interventions: Drug: Fruquintinib;   Drug: Gefitinib
32 Not yet recruiting Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer
Condition: NSCLC
Interventions: Radiation: Conventional Fractionated Radiotherapy;   Radiation: Stereotactic Body Radiation Therapy
33 Not yet recruiting Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
Condition: NSCLC
Intervention: Drug: Alflutinib
34 Recruiting Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
Condition: Extensive Stage Small Cell Lung Cancer
Intervention: Drug: temozolomide
35 Recruiting N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation
Conditions: Non-small-Cell Lung Carcinoma;   Surgery;   Stage IIIA-N2;   Chemoradiation;   Survival
Intervention: Other: Overall survival
36 Recruiting Study of ASN003 in Subjects With Advanced Solid Tumors
Conditions: Neoplasms;   Melanoma;   Colorectal Neoplasm;   Carcinoma, Non-small Cell Lung
Interventions: Drug: ASN003 ascending doses;   Drug: ASN003 MTD
37 Recruiting High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Icotinib
38 Recruiting Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Condition: Progression Free Survival
Interventions: Drug: Osimertinib;   Drug: docetaxel, bevacizumab
39 Recruiting Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer
Condition: Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
40 Recruiting Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Glesatinib;   Drug: Sitravatinib;   Drug: Mocetinostat;   Drug: Nivolumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.